Why the study?
Does aspirin or ticlopidine alter the formation of different sizes of platelet aggregates compared to controls?
Population
115 subjects, comprising 47 controls, 31 patients treated with aspirin, and 37 patients treated with…
Comparison
Aspirin (330 mg/day) or ticlopidine (200 mg/day) vs Controls (untreated with antiplatelet medication)
Design
Cross-sectional
Authors
Loading...
May inform differential antiplatelet mechanisms by aggregate size; leaves open clinical outcome relevance.
Does aspirin or ticlopidine alter the formation of different sizes of platelet aggregates compared to controls?
The laser-light scattering method reveals distinct mechanisms of platelet aggregate inhibition by aspirin and ticlopidine depending on aggregant concentration.
Tohgi et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: